Activation of pyroptosis and immunogenic cell death by targeted liposomal cisplatin for enhanced chemo-immunotherapy for osteosarcoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Osteosarcoma10.1038/s41572-022-00409-y ↗
2. Advances on immunotherapy for osteosarcoma10.1186/s12943-024-02105-9 ↗
3. Future directions in the treatment of osteosarcoma10.3390/cells10010172 ↗
4. Osteosarcoma in children: not only chemotherapy10.3390/ph14090923 ↗
5. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies10.3390/ijms21186885 ↗
6. ROS responsive nanoparticles mediated inhibition of monocarboxylic acid transporters to enhance chemoimmunotherapy by overcoming low immune response in osteosarcoma10.1016/j.nantod.2023.102057 ↗
7. Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
8. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
9. Dual-responsive nanoparticles targeting bone microenvironment for synergistic chemoimmunotherapy of osteosarcoma by remodeling immune microenvironment10.1016/j.nantod.2023.101877 ↗
10. Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy10.1016/j.biomaterials.2022.121856 ↗
11. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
12. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review10.2147/IJN.S243223 ↗
13. The uniqueness of albumin as a carrier in nanodrug delivery10.1021/acs.molpharmaceut.1c00046 ↗
14. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
15. Targeted therapy for hepatocellular carcinoma10.1038/s41392-020-00264-x ↗
16. PD-L1 status in breast cancer: current view and perspectives10.1016/j.semcancer.2019.12.003 ↗
17. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs10.1016/j.canlet.2020.12.024 ↗
18. Promise and challenges of T cell immunotherapy for osteosarcoma
19. Macrophages in osteosarcoma immune microenvironment: implications for immunotherapy10.3389/fonc.2020.586580 ↗
20. Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy10.3389/fphar.2023.1271321 ↗
21. Pyroptosis in inflammatory diseases and cancer10.7150/thno.71086 ↗
22. NLRP3 and pyroptosis blockers for treating inflammatory diseases10.1016/j.tips.2022.04.003 ↗
23. Cell death10.1016/j.cell.2023.11.044 ↗
24. Pyroptosis, metabolism, and oxidation in tumorigenesis: mechanisms and therapeutic implications10.1089/ars.2023.0257 ↗
25. Mechanistic insights into gasdermin pore formation and regulation in pyroptosis10.1016/j.jmb.2021.167297 ↗
26. Gasdermin D in pyroptosis10.1016/j.apsb.2021.02.006 ↗
27. Pyroptosis at the forefront of anticancer immunity10.1186/s13046-021-02065-8 ↗
28. The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles10.1038/s41419-023-06382-y ↗
29. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming10.1038/s41467-020-20696-x ↗
30. Decitabine treatment induces a viral mimicry response in cervical cancer cells and further sensitizes cells to chemotherapy10.3390/ijms232214042 ↗
31. Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells10.1371/journal.pone.0282244 ↗
32. Mitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage10.1016/j.devcel.2022.03.019 ↗
33. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy10.1186/s12951-024-02297-8 ↗
34. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death10.1038/s41467-020-19970-9 ↗
35. Inducing immunogenic cell death in immuno-oncological therapies10.21147/j.issn.1000-9604.2022.01.01 ↗
36. DAMPs in immunosenescence and cancer10.1016/j.semcancer.2024.09.005 ↗
37. Release mechanisms of major DAMPs10.1007/s10495-021-01663-3 ↗
38. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases10.1111/imr.12534 ↗
39. Cancer cell metabolism and antitumour immunity10.1038/s41577-024-01026-4 ↗
40. Structure and function of the immune system in the spleen10.1126/sciimmunol.aau6085 ↗
41. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy10.1016/j.ccell.2023.02.014 ↗
42. Targeting tumor-infiltrating tregs for improved antitumor responses
43. Can cisplatin therapy be improved? Pathways that can be targeted10.3390/ijms23137241 ↗
44. Neoadjuvant chemotherapy for adults with osteogenic sarcoma10.1007/s11864-024-01269-2 ↗